Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders
First Claim
Patent Images
1. A composition comprising at least one mRNA, wherein said at least one mRNA comprisesa first region of linked nucleosides, said first region encoding SEQ ID NO 909, and wherein said first region comprises a coding region having at least 80% identity to SEQ ID NO:
- 9244.
2 Assignments
0 Petitions
Accused Products
Abstract
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
1017 Citations
8 Claims
-
1. A composition comprising at least one mRNA, wherein said at least one mRNA comprises
a first region of linked nucleosides, said first region encoding SEQ ID NO 909, and wherein said first region comprises a coding region having at least 80% identity to SEQ ID NO: - 9244.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8)
-
2. The composition of claim 1, wherein the at least one mRNA comprises a poly-A tail.
-
3. The composition of claim 2, wherein the at least one mRNA comprises a 5′
- cap structure.
-
4. The composition of claim 2, wherein the at least one mRNA is purified.
-
5. The composition of claim 1, comprising a pharmaceutically acceptable excipient.
-
6. The composition of claim 5, wherein the pharmaceutically acceptable excipient is selected from the group consisting of a solvent, aqueous solvent, nonaqueous solvent, dispersion media, diluent, dispersion, suspension aid, surface active agent, isotonic agent, thickening or emulsifying agent, preservative, lipid, lipidoids liposome, lipid nanoparticle, core-shell nanoparticles, polymer, lipoplex, peptide, protein, cell, hyaluronidase, and mixtures thereof.
-
7. The composition of claim 1, wherein the coding region of the mRNA is selected from the group consisting of SEQ ID NOs:
- 9244, 9243, 9264, 9280, 9305, 9308, 9316, 9318, and 9327.
-
8. A method of producing Factor X, in a cell, tissue, or organism comprising contacting said cell, tissue, or organism with the at least one mRNA of claim 1.
-
2. The composition of claim 1, wherein the at least one mRNA comprises a poly-A tail.
Specification
- Resources
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeModerna TX, Inc. (Moderna, Inc.)
-
Original AssigneeModerna Therapeutics, Inc. (Moderna, Inc.)
-
InventorsChakraborty, Tirtha, de Fougerolles, Antonin
-
Primary Examiner(s)GALISTEO GONZALEZ, ANTONIO
-
Application NumberUS14/104,591Publication NumberTime in Patent Office761 DaysField of SearchNoneUS Class Current1/1CPC Class CodesA61K 31/7115 Nucleic acids or oligonucle...A61K 38/00 Medicinal preparations cont...A61K 38/17 from animals; from humans e...A61K 38/177 Receptors; Cell surface ant...A61K 38/1816 Erythropoietin [EPO]A61K 38/1891 Angiogenesic factors; Angio...A61K 38/191 Tumor necrosis factors [TNF...A61K 38/193 Colony stimulating factors ...A61K 38/212 IFN-alphaA61K 38/45 Transferases (2)A61K 38/4846 Factor VII (3.4.21.21); Fac...A61K 47/543 Lipids, e.g. triglycerides;...A61K 48/0033 the non-active part being n...A61K 48/0041 the non-active part being p...A61K 48/005 characterised by an aspect ...A61K 48/0066 Manipulation of the nucleic...A61K 48/0075 characterised by an aspect ...A61K 9/0019 Injectable compositions; In...A61K 9/1271 Non-conventional liposomes,...A61K 9/145 with organic compoundsA61K 9/5123 : Organic compounds, e.g. fat...A61K 9/5146 : obtained otherwise than by ...A61K 9/5153 : Polyesters, e.g. poly(lacti...A61P 1/00 : Drugs for disorders of the ...A61P 1/04 : for ulcers, gastritis or re...A61P 11/00 : Drugs for disorders of the ...A61P 13/00 : Drugs for disorders of the ...A61P 13/12 : of the kidneysA61P 15/00 : Drugs for genital or sexual...A61P 17/00 : Drugs for dermatological di...A61P 17/02 : for treating wounds, ulcers...A61P 17/04 : AntipruriticsA61P 17/06 : AntipsoriaticsA61P 17/08 : AntiseborrheicsA61P 17/14 : for baldness or alopeciaA61P 19/00 : Drugs for skeletal disordersA61P 19/02 : for joint disorders, e.g. a...A61P 19/10 : for osteoporosisA61P 21/00 : Drugs for disorders of the ...A61P 21/04 : for myasthenia gravisA61P 25/00 : Drugs for disorders of the ...A61P 25/02 : for peripheral neuropathiesA61P 25/14 : for treating abnormal movem...A61P 25/18 : Antipsychotics, i.e. neurol...A61P 25/24 : AntidepressantsA61P 25/28 : for treating neurodegenerat...A61P 25/30 : for treating abuse or depen...A61P 27/02 : Ophthalmic agentsA61P 29/00 : Non-central analgesic, anti...A61P 3/00 : Drugs for disorders of the ...A61P 3/06 : AntihyperlipidemicsA61P 3/10 : for hyperglycaemia, e.g. an...A61P 31/00 : Antiinfectives, i.e. antibi...A61P 31/04 : Antibacterial agentsA61P 31/10 : AntimycoticsA61P 31/12 : AntiviralsA61P 31/14 : for RNA virusesA61P 31/18 : for HIVA61P 35/00 : Antineoplastic agentsA61P 35/02 : specific for leukemiaA61P 35/04 : specific for metastasisA61P 37/00 : Drugs for immunological or ...A61P 37/02 : ImmunomodulatorsA61P 37/06 : Immunosuppressants, e.g. dr...A61P 37/08 : Antiallergic agents antiast...A61P 43/00 : Drugs for specific purposes...A61P 5/00 : Drugs for disorders of the ...A61P 7/00 : Drugs for disorders of the ...A61P 7/02 : Antithrombotic agents; Anti...A61P 7/04 : Antihaemorrhagics; Procoagu...A61P 7/06 : AntianaemicsA61P 9/00 : Drugs for disorders of the ...A61P 9/10 : for treating ischaemic or a...C07H 21/02 : with ribosyl as saccharide ...C07K 14/005 : from virusesC07K 14/435 : from animals; from humansC07K 14/43595 : from coelenteratae, e.g. me...C07K 14/47 : from mammalsC07K 14/4705 : stimulating, promoting or a...C07K 14/4713 : Autoimmune diseases, e.g. I...C07K 14/4723 : Cationic antimicrobial pept...C07K 14/4746 : p53C07K 14/475 : Growth factors; Growth regu...C07K 14/485 : Epidermal growth factor [EG...C07K 14/495 : Transforming growth factor ...C07K 14/505 : Erythropoietin [EPO]C07K 14/515 : Angiogenesic factors; Angio...C07K 14/525 : Tumour necrosis factor [TNF]C07K 14/535 : Granulocyte CSF; Granulocyt...C07K 14/5418 : IL-7C07K 14/56 : IFN-alphaC07K 14/61 : Growth hormone [GH], i.e. s...C07K 14/62 : InsulinsC07K 14/705 : Receptors; Cell surface ant...C07K 14/745 : Blood coagulation or fibrin...C07K 16/00 : Immunoglobulins [IGs], e.g....C07K 16/2863 : against receptors for growt...C07K 16/2887 : against CD20C07K 16/40 : against enzymesC12N 15/11 : DNA or RNA fragments; Modif...C12N 15/52 : Genes encoding for enzymes ...C12N 15/85 : for animal cellsC12N 15/87 : Introduction of foreign gen...C12N 15/88 : using microencapsulation, e...C12N 9/0069 : acting on single donors wit...C12N 9/0091 : oxidizing metal ions (1.16)C12N 9/1051 : Hexosyltransferases (2.4.1)C12N 9/1241 : Nucleotidyltransferases (2....C12N 9/16 : acting on ester bonds (3.1)C12N 9/2402 : hydrolysing O- and S- glyco...C12N 9/2445 : Beta-glucosidase (3.2.1.21)C12N 9/6435 : Plasmin (3.4.21.7), i.e. fi...C12N 9/6437 : Coagulation factor VIIa (3....C12N 9/644 : Coagulation factor IXa (3.4...C12N 9/6443 : Coagulation factor XIa (3.4...C12N 9/6451 : Coagulation factor XIIa (3....C12N 9/88 : Lyases (4.)C12N 9/93 : Ligases (6)C12P 13/04 : Alpha- or beta- amino acids...C12P 21/00 : Preparation of peptides or ...C12P 21/005 : Glycopeptides, glycoproteinsC12Y 113/12007 : Photinus-luciferin 4-monoox...C12Y 116/03001 : Ferroxidase (1.16.3.1), i.e...C12Y 207/07012 : UDP-glucose--hexose-1-phosp...C12Y 304/21007 : Plasmin (3.4.21.7), i.e. fi...C12Y 304/21022 : Coagulation factor IXa (3.4...C12Y 304/21027 : Coagulation factor XIa (3.4...C12Y 403/02001 : Argininosuccinate lyase (4....C12Y 603/02019 : Ubiquitin-protein ligase (6...Y02A 50/30 : Against vector-borne diseas...